Sanofi Expands Oncology Portfolio with NK Cell Engager In-License from Innate Pharma
Sanofi (NASDAQ: SNY) has in-licensed a natural killer (NK) cell engager candidate for solid tumors...
NYSE: BMY
BMS Partners with Terray Therapeutics for AI-Driven Drug Discovery
Bristol Myers Squibb (BMS; NYSE: BMY) has entered into an agreement with U.S.-based Terray Therapeutics...
BMS Presents Promising Golcadomide Trial Results for Non-Hodgkin Lymphomas
Bristol Myers Squibb (BMS; NYSE: BMY) has presented results from Phase I and Phase I/II...
BMS Advances TIGITxCD96 Bispecific Antibody into Phase II Dose Expansion
Bristol Myers Squibb (BMS; NYSE: BMY) has advanced its development program for the TIGITxCD96 bispecific...
Sichuan Biokin and Bristol Myers Squibb Ink USD 8.4 Billion Licensing Deal for ADC Candidate
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a Chinese pharmaceutical company, has announced a landmark...
BMS Broadens Scope of IMID Collaboration, Aiming for Deeper Insights into Sjögren’s and Atopic Dermatitis
Bristol Myers Squibb (BMS; NYSE: BMY) has expanded its 2016 partnership with IMIDomics, broadening the...
CAR T-Cell Therapy Stocks Plunge as FDA Investigates Cancer Reports Linked to Treatments
Shares of Chimeric Antigen Receptor (CAR) T cell therapy companies plummeted on November 28, 2023,...
BMS and Avidity Biosciences Join Forces on $2.2 Billion Cardiology Antibody Oligonucleotide Conjugate Deal
Bristol Myers Squibb (BMS, NYSE: BMY) has announced a strategic partnership with Avidity Biosciences (NASDAQ:...
BMS and 2seventy Bio’s Abecma Faces FDA Review Extension
The US Food and Drug Administration (FDA) has postponed the target action date for Bristol...
BMS’s Augtyro Receives FDA Approval for ROS1-Positive NSCLC
The US Food and Drug Administration (FDA) has granted Bristol Myers Squibb (BMS, NYSE: BMY)...
EMA’s CHMP Issues Positive Opinion for Roche’s Tecentriq SC Subcutaneous Formulation
The Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA)...
BMS Secures ORM-6151 for Acute Myeloid Leukemia Treatment with Orum Therapeutics Deal
Bristol Myers Squibb (BMS; NYSE: BMY) has made a significant move in the field of...
Boan Biotech Enrolls First Patient in Phase III Study for Opdivo Biosimilar BA1104 in China
Boan Biotech (HKG: 6955), a biopharmaceutical company based in China, has announced the enrollment of...
BMS and Karyopharm Partner to Evaluate Mezigdomide and Xpovio in Relapsed/Refractory Multiple Myeloma
Bristol Myers Squibb (BMS; NYSE: BMY) has entered into a collaboration and supply agreement with...
BMS Revenue Slips Due to Revlimid Erosion: Q3 2023 Insights
Bristol Myers Squibb (BMS; NYSE: BMY) reported a 3% year-on-year (YOY) revenue decline, excluding foreign...
BMS’s BMS-986278 Receives FDA Breakthrough Therapy Designation for Pulmonary Fibrosis
Bristol-Myers Squibb (BMS; NYSE: BMY) announced this week that it has received breakthrough therapy designation...
BMS Regains Full Rights to Mavacamten in China and Asia from LianBio
Bristol-Myers Squibb (BMS; NYSE: BMY) is set to regain full control of mavacamten, a treatment...
BMS’s Sotyktu Receives NMPA Approval for Psoriasis Treatment
The National Medical Products Administration (NMPA) has granted regulatory approval to US-based pharmaceutical major Bristol-Myers...
BMS’s Subcutaneous Opdivo Meets Phase III Study Endpoints in ccRCC
Bristol-Myers Squibb (BMS; NYSE: BMY) has announced positive results from a Phase III comparative study...
BMS Expands CAR-T Collaboration with Cellares on Automation Tech
Bristol-Myers Squibb (BMS; NYSE: BMY) has entered into a technology transfer agreement with US-based Cellares,...